



PB 114 of 2015

National Health (Originator Brand) Amendment Determination 2015 (No. 1)

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the *National Health Act 1953*.

Dated 26 November 2015

ADRIANA PLATONA

Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health

1 Name of Determination

- (1) This Determination is the *National Health (Originator Brand) Amendment Determination 2015 (No. 1)*.
- (2) This Determination may also be cited as PB 114 of 2015.

2 Commencement

This Determination commences on 1 December 2015.

3 Amendments to PB 100 of 2015

Schedule 1 amends the *National Health (Originator Brand) Determination 2015* (PB 100 of 2015).

Schedule 1 Amendments

(section 3)

[1] Schedule 1 (table item 44)

Repeal the item, substitute:

44	Clarithromycin	Klacid		
----	----------------	--------	--	--

[2] Schedule 1 (after table item 114)

Insert:

114A	Infliximab	Remicade		
------	------------	----------	--	--

[3] Schedule 1 (after table item 204)

Insert:

204A	Rizatriptan	Maxalt		
------	-------------	--------	--	--

[4] Schedule 1 (after table item 211)

Insert:

211A	Somatropin	Genotropin Genotropin GoQuick Genotropin MiniQuick		
------	------------	--	--	--

[5] Schedule 1 (table item 239)

Repeal the item, substitute:

239	Valaciclovir	Valtrex		
-----	--------------	---------	--	--

[6] Schedule 1 (table item 242)

Repeal the item, substitute:

242	Valsartan with hydrochlorothiazide	Co-Diovan 80/12.5 Co-Diovan 160/12.5 Co-Diovan 160/25 Co-Diovan 320/12.5 Co-Diovan 320/25		
-----	---------------------------------------	---	--	--

[7] Schedule 1 (after table item 247)

Insert:

247A	Zoledronic acid	Aclasta Zometa		
------	-----------------	-------------------	--	--